Regeneron and SillaJen evaluate oncolytic virus combo therapy for kidney cancer
Executive Summary
Regeneron Pharmaceuticals Inc. and SillaJen Corp. have planned a Phase Ib dose-escalation study as part of a trial collaboration evaluating the combination of Regeneron’s PD-1 inhibitor REGN2810 and SillaJen’s oncolytic vaccinia virus Pexa-Vec (pexastimogene devacirepvec) for patients with previously treated metastatic or unresectable renal cell carcinoma.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice